Related Experiment Video
Updated: Aug 29, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer
Chandrasekharan Rajalekshmi Dhanya1, Aarcha Shanmugha Mary2, Maya Madhavan3
1Department of Biochemistry, Government College Kariavattom, Thiruvananthapuram, India.
Abstract:
RNA interference is a transformative approach and has great potential in the development of novel and more efficient cancer therapeutics. Immense prospects exist in the silencing of HER2 and its downstream genes which are overexpressed in many cancers, through exogenously delivered siRNA. However, there is still a long way to exploit the full potential and versatility of siRNA therapeutics due to the challenges associated with the stability and delivery of siRNA targeted to specific sites. Aptamers offer several advantages as a vehicle for siRNA delivery, over other carriers such as antibodies. In this review, we discuss the progress made in the development and applications of aptamer-siRNA chimeras in HER2 targeting and gene silencing. A schematic workflow is also provided which will provide ample insight for all those researchers who are new to this field. Also, we think that a mechanistic understanding of the HER2 signaling pathway is crucial in designing extensive investigations aimed at the silencing of a wider array of genes. This review is expected to stimulate more research on aptamer-siRNA chimeras targeted against HER2 which might arm us with potential effective therapeutic interventions for the management of cancer.
Insights
Aptamer-siRNA chimeras show promise for cancer therapy by silencing HER2 (Human Epidermal growth factor Receptor 2). This review explores their development and application for targeted gene silencing and potential cancer treatment.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Therapeutics
Background:
- RNA interference (RNAi) offers potential for novel cancer therapeutics.
- HER2 overexpression in cancers presents a target for gene silencing via small interfering RNA (siRNA).
- Challenges in siRNA stability and targeted delivery hinder therapeutic development.
Purpose of the Study:
- To review the progress in developing aptamer-siRNA chimeras for HER2 targeting.
- To discuss the application of these chimeras in gene silencing.
- To provide insights for researchers entering the field of aptamer-siRNA therapeutics.
Main Methods:
- Review of existing literature on aptamer-siRNA chimera development.
- Discussion of HER2 signaling pathways and gene silencing mechanisms.
- Presentation of a schematic workflow for aptamer-siRNA chimera design.
Main Results:
- Aptamers offer advantages over other carriers for siRNA delivery.
- Aptamer-siRNA chimeras demonstrate potential for targeted HER2 gene silencing.
- Mechanistic understanding of HER2 signaling is key for broader gene silencing applications.
Conclusions:
- Aptamer-siRNA chimeras are a promising strategy for HER2-targeted cancer therapy.
- Further research is needed to overcome delivery and stability challenges.
- This approach may lead to effective therapeutic interventions for cancer management.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi